We recently published a list of 15 Best Defensive Stocks Amid Market Volatility In this article, we are going to take a look ...

Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

ANI Pharmaceuticals (ANIP) has completed the buyout of its 3.125% perpetual royalty obligation to SWK Funding on worldwide net revenues of ...

Collegium Pharmaceutical Inc. is a specialty pharma ... They have a deferred royalty obligation, and the balance is currently $120 million, which is part of the net debt calculation.

Royalty Pharma plc (NASDAQ:RPRX – Get Free Report) has received an average recommendation of “Buy” from the six analysts that are currently covering the company, Marketbeat.com reports.

Royalty Pharma is planning the biggest IPO of the year as the market’s appetite for biotech stocks remains strong. The company said in a filing with the US financial regulator that it plans ...

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on ...

Royalty Pharma plc has a one year low of $24.05 and a one year high of $34.20. The business’s 50-day simple moving average is $29.71 and its 200 day simple moving average is $28.09.